Press Releases
Nov 30, 2023
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

– Results of pivotal confirmatory trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall survival and progression-free survival vs standard platinum...

Nov 29, 2023
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy

Phase 3b DAYLIGHT study being presented at ESG 2023 demonstrated fezolinetant 45 mg achieved statistically significant reductions in the frequency and severity of moderate to severe vasomotor...

Nov 16, 2023
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting

XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy* in nonmetastatic castration-sensitive prostate cancer TOKYO and NEW YORK

EXPLORE ALL US PRESS RELEASES

Articles
Oct 10, 2023
Astellas Recognized as a Top Company for Working Parents

Astellas ranked in Seramount’s 2023 “100 Best Companies” list for the ninth consecutive year This year, Astellas once again was named as a top company for working parents on Seramount’s...

Oct 10, 2023
Meet our 2023 Working Parents of the Year

Astellas was once again ranked in Seramount’s 2023 list of 100 Best Companies confirming our commitment to creating a supportive workplace for working parents. This year, Astellas is proud to...

Oct 2, 2023
Astellas Celebrates Global Diversity Awareness Month – Honoring our Commitment to Expanding and Evolving EDEI Globally

Astellas reflects on the importance of engagement, diversity, equity and inclusion in fostering a people-centric culture. Astellas is proud to celebrate Global Diversity Awareness Month this...

EXPLORE ALL ARTICLES

Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

 

For media inquiries and reporter requests, please click here to fill out a request form.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.

 

Astellas on Twitter
Download Fact Sheet

Download Fact Sheet

Sustainability

Sustainability

Investors

Investors

Explore U.S. Products

Explore U.S. Products